Abstract 1123P
Background
Although the presence of tumor-infiltrating lymphocytes (TILs) in pathological specimens has been associated with prolonged survival in melanoma, it is largely unknown whether TILs can predict response to immune checkpoint inhibition (ICI) in advanced melanoma. Therefore, we investigated the association between treatment response and TILs in the largest cohort to date.
Methods
Patients who received first-line anti-PD1 ± anti-CTLA4 for advanced cutaneous melanoma were retrospectively identified from nine hospitals in the Netherlands. TILs were scored as absent, non-brisk or brisk on hematoxylin and eosin (H&E) slides of primary melanoma and pre-treatment metastases. The primary outcome was clinical response to ICI according to RECIST 1.1. Univariable and multivariable logistic regression analyses were performed and Kaplan-Meier methods were used for survival analyses.
Results
Metastatic melanoma specimens were available for 676 patients, whereas primary melanomas were available from 436 patients. TILs were absent in 347, non-brisk in 260 and brisk in 69 metastases. Compared to patients with absent TILs, both patients with non-brisk TILs (odds ratio [OR] 1.74, 95% confidence interval [CI] 1.25-2.43) and brisk TILs (OR 3.58, 95%CI 2.01-6.64) had a higher probability of response to ICI. This association remained in multivariable analysis, adjusted for age, sex, disease stage, lactate dehydrogenase level and World Health Organisation performance score (see table). Patients with absent TILs had a shorter median progression-free survival (PFS) compared to patients with non-brisk TILs and brisk TILs (6.2, 10.6 and 19.3 months, respectively [p=0.003]). No significant association was found between TILs in primary melanoma specimens and response. Table: 1123P
Objective response rate (ORR), odds ratio (OR) and adjusted OR for response, median progression-free survival (PFS) and overall survival (OS) in months, stratified by TIL score on 676 pre-treatment metastatic specimens of advanced melanoma patients treated with ICI
TIL score | ||||
Absent | Non-brisk | Brisk | p-value | |
ORR | 45% | 58% | 74% | |
OR [95% CI] for response (univariable) | REF | 1.74 [1.25-2.43] | 3.58 [2.01-6.64] | <0.001 |
OR [95% CI] for response (multivariable) | REF | 1.61 [1.13-2.32] | 3.09 [1.68-5.92] | <0.001 |
Median PFS [95% CI] | 6.2 [5.4-9.0] | 10.6 [6.4-not reached] | 19.3[9.5-not reached] | 0.003 |
Median OS [95% CI] | 19.8 [15.4-29.4] | 49.4 [25.7-not reached] | 40.8[23.5-not reached] | 0.003 |
Conclusions
The presence of non-brisk and brisk TILs in pre-treatment metastatic H&E histopathology specimens is associated with better response to ICI and survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hanarth Fonds.
Disclosure
M. Labots: Financial Interests, Institutional, Advisory Role: Bristol Myers Squibb, Janssen-Cilag B.V. K.P.M. Suijkerbuijk: Financial Interests, Institutional, Advisory Board: Novartis, BMS, AbbVie, Pierre Fabre, MSD; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Grant: Novartis, TigaTx. All other authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13